Welcome to our dedicated page for Titan Pharmaceut news (Ticker: TTNP), a resource for investors and traders seeking the latest updates and insights on Titan Pharmaceut stock.
Titan Pharmaceuticals, Inc. (formerly Nasdaq: TTNP) has generated a series of material news events that trace its evolution from a development stage biopharmaceutical company centered on the ProNeura long-term, continuous drug delivery technology to a wholly owned subsidiary within a new holding company structure. News coverage for TTNP spans technology development, asset sales, capital raising, corporate governance, listing status, and a transformative reverse merger.
Earlier news releases describe Titan as a development stage company developing proprietary therapeutics using ProNeura, with potential applications in chronic conditions where consistent, around-the-clock blood levels of medication may benefit patients. Subsequent announcements highlight a significant asset sale to Fedson, Inc., in which Titan agreed to sell certain ProNeura assets, including its portfolio of drug addiction products (Probuphine and Nalmefene implant programs) and other early development programs based on the ProNeura platform, in exchange for upfront consideration, potential milestone payments, and royalties.
Investors following TTNP-related news will also find detailed reports on multiple private placements of convertible preferred stock, including Series AA preferred stock sold to The Sire Group Ltd. and Series B and Series C preferred stock issued to Blue Harbour Asset Management L.L.C-FZ. These transactions, described in press releases and 8-K filings, include conversion features and ownership limitations linked to Nasdaq listing rules, and are accompanied by registration rights agreements.
Corporate and listing developments form another key stream of Titan news. The company announced a 1-for-20 reverse stock split of its common stock, later reported that it had regained compliance with Nasdaq’s minimum bid price requirement, and then disclosed Nasdaq notices related to periodic reporting and audit committee composition. The most consequential news items concern Titan’s Merger and Contribution and Share Exchange Agreement with TalenTec Sdn. Bhd. (formerly KE Sdn. Bhd.) through Black Titan Corporation, and the subsequent completion of this reverse merger, after which TTNP common stock was expected to cease trading on the Nasdaq Capital Market.
For readers researching TTNP, this news archive provides a chronological view of Titan’s strategic alternatives process, key financing decisions, asset divestitures, board changes, and the final steps leading to its combination with TalenTec and the transition of its public listing to Black Titan ordinary shares. Regular review of these historical news items helps contextualize the company’s path and the regulatory filings associated with its corporate transformation.
Titan Pharmaceuticals (NASDAQ: TTNP) has completed a private placement of Series C Convertible Preferred Stock with Blue Harbour Asset Management. The placement involves 60,000 shares at a conversion price of $3.40, raising an aggregate of $600,000.
The agreement includes a beneficial ownership conversion blocker limiting Blue Harbour's ownership to the lower of Nasdaq permissible limits or 19.99% of outstanding common stock. The transaction was conducted under Regulation S of the Securities Act, with ARC Group Ltd. serving as the sole financial advisor.
Titan Pharmaceuticals (NASDAQ: TTNP) has completed a $1 million private placement through the sale of Series B Convertible Preferred Stock to Blue Harbour Asset Management. The agreement involves the purchase of 100,000 preferred shares at a conversion price of $3.00.
The deal includes a beneficial ownership conversion blocker that prevents Blue Harbour from acquiring more than 19.99% of Titan's outstanding common stock or the maximum percentage permissible under Nasdaq rules without shareholder approval. The shares were sold through a private placement under Regulation S of the Securities Act.
The companies have also entered into a registration rights agreement, with ARC Group serving as the sole financial advisor for the transaction.
Titan Pharmaceuticals (NASDAQ: TTNP) has received two notices from Nasdaq regarding listing compliance issues. The first notice on November 22, 2024, concerns the company's failure to file its Q3 2024 Form 10-Q on time. Titan has until January 21, 2025, to submit a compliance plan and may receive up to 180 days (until May 19, 2025) to file the report. The second notice on November 25, 2024, addresses non-compliance with audit committee requirements following Brynner Chiam's appointment. The company has until November 6, 2025, to resolve this issue and plans to appoint an additional independent director to the Board and Audit Committee.
Titan Pharmaceuticals (NASDAQ: TTNP) has entered into a Merger Agreement with KE Sdn. Bhd. for a reverse merger transaction. The deal involves a two-step process: TTNP Merger Sub will merge with Titan, making Titan a wholly-owned subsidiary of BSKE KE shareholders can then exchange their shares for BSKE ordinary shares. Post-merger, KE and Titan shareholders are expected to own 86.7% and 13.3% of the combined company, respectively. Dato' Seow Gim Shen, Titan's CEO and KE's major shareholder, will own 48.9% of the combined entity. The merger aims to create value for Titan stockholders by combining with KE, a distributor of human capital management solutions in Asia Pacific. The deal is subject to stockholder approval, Nasdaq listing approval, and other customary conditions.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.